Nouveau labo! Je cherche des étudiant(e)s gradué(e)s voulant travailler dans le domaine de l'épissage de l'ARN en #cancer et #immunologie. New lab! I'm looking for grad students interested in #RNAsplicing in #cancer and #immunology https://t.co/BwcE57iEwh @jrRNAscientists

Oops I did it again: A single, searchable, sortable, spreadsheet of all presentations at #ISMBECCB2023 https://t.co/106jgmmcIP Have fun planning your conference!

@ABG_Asso

RT @iRnaCosi@genomic.social Reminder of our upcoming online journal club tomorrow, May 2 at 15:30GMT/11:30EDT/8:30PT. We will be discussing RNA structural switches discovery with 1st author khorms57 Register: https://t.co/Dye0BzBaNC RNASociety iscb https://t.co/1Uwsi9Nzmx

May: https://t.co/mqhQNjhhLL https://t.co/iRso04UWYd (2/2)

RT @BiologyOpen@mstdn.science Our sister journals Dev_journal J_Cell_Sci J_Exp_Biol & DMM_Journal offer Travelling Fellowships of up to £3,000 to #biology #PhD students & #Postdocs wishing to make collaborative visits to other laboratories. Next application deadline is 5 (1/2)

switches. https://t.co/EG0DAvOcLj Free registration: https://t.co/4iA4rbCiOu iscb RNASociety https://t.co/xsoWjLKt8a (2/2)

RT @iRnaCosi@genomic.social Thrilled to announce our upcoming journal club, May 2, 11:30am EDT (15:30GMT). Dr. Matvei Khoroshkin, postdoc in genophoria lab at UCSF, will present results from their preprint on the discovery of RNA structural (1/2)

exactly why the reputation of #journalism everywhere has been dragged through the mud. You are all simply puppets if you cannot create, support and / or foster a framework that supports journalistic freedom and integrity. https://t.co/3SjJbSJoFK (2/2)

RT @Suig@mstdn.party #NPR should run their own #Mastodon instance as should every other serious news outfit. This bullshit where supposedly serious news organizations should have to capitulate to the whims of some narcissistic billionaire or corrupt government is (1/2)

prospects, and quality of life https://t.co/25tkxquSW1 (2/2)

The NIH will be taking comments from the postdoc community over the next few days. Topics of high importance are on the agenda: - Role, duration, structure, and value of the postdoc - International trainee concerns - Compensation and benefits - Job security, career (1/2)

#ONpoli #HamOnt #InducedTravel #InducedDemand https://t.co/fnTI92NQgW https://t.co/fVATf07kGV (2/2)

RT @mbonsma@mastodon.social A major escarpment access in #Hamilton is closing on short notice. Should you be worried about increased congestion because of detours? Surprisingly, probably not! A thread about "traffic evaporation", the cool cousin of induced demand. (1/2)

tag. https://t.co/b0olBG8kib https://t.co/fPEexlXo8T (3/3)

patients anywhere in the developing world. And they say that's on purpose: that the maker, Vertex Pharmaceuticals, is deliberately obstructing access so as to be able to maintain that price (2/3)

RT @snolen@journa.host Maybe you've heard about Trikafta, the 'miracle' drug that has transformed life for people with cystic fibrosis in North America and Europe? It costs $322,000 a year, and patients take it for life. Turns out the drug isn't available for CF (1/3)

#lymphoma. #FollicularLymphoma #Hematology #MonoclonalAntibody #DrugDevelopment https://t.co/rXpwRGl3v5 https://t.co/bzoDMU7cDa (2/2)

RT @cyrilpedia@qoto.org My latest clinical pipeline column for NatureMedicine is out today. It's a look at the recent approval of mosunetuzumab, #Genentech's bispecific anti CD20/CD3 monoclonal antibody for relapsed or refractory follicular (1/2)

#journals. https://t.co/RXvs5W0sJO https://t.co/AxjYyWRLBK (2/2)